Geneseeq’s PanTRKare Gains NMPA Approval for Eratrectinib Diagnosis

The PanTRKare assay addresses significant technical hurdles in oncology testing, specifically the low incidence and complex fusion patterns of NTRK1/2/3 variants. Bridging study results confirmed that the diagnostic maintains high consistency with clinical trial data for Eratrectinib, delivering reliable results for both treatment-naïve and pre-treated populations. This validation ensures that clinicians can accurately deploy the drug to maximize patient response rates across diverse cancer types.

Eratrectinib itself represents a milestone for Nanjing’s pharmaceutical sector, utilizing cyclic structural optimization to outperform first-generation inhibitors. Clinical data from the VC004-101 trial highlight the drug's efficacy, with an overall response rate of 68.5% that climbs to 89.7% among patients followed for over six months. Furthermore, the therapy demonstrates durable disease control, evidenced by a 2-year progression-free survival rate of 75.7% and a median overall survival of 40.7 months.

The rapid alignment of these two approvals—coming just two months after the drug hit the market—highlights a successful collaboration between Vcare PharmaTech and Geneseeq. Both companies operate within the Nanjing Jiangbei New Area, leveraging the region's industrial ecosystem to bridge the gap between diagnostic development and therapeutic administration. This integration significantly reduces the time required for eligible patients to access targeted care.